Artivion to Announce Fourth Quarter Financial Results
Artivion, Inc. (NYSE: AORT), a renowned company in the cardiac and vascular sector, has set a date for the release of its fourth quarter financial results for the year 2025. The main announcement will occur on the afternoon of the market closing on February 12, 2026. This release is highly anticipated within investor circles and highlights the firm’s dedication to transparency and clear communication.
Details of the Teleconference Call
On the same day as the financial results announcement, Artivion will host a teleconference call and live webcast intended for analysts, investors, and anyone interested in learning more about their financial performance. The session will kick off at 4:30 p.m. ET, featuring a comprehensive discussion of the results. Pat Mackin, the esteemed Chairman, President, and CEO of Artivion, will lead this insightful session, which will also include a question-and-answer segment designed to engage stakeholders and address any inquiries.
Accessing the Teleconference
For those wishing to join the teleconference live, participants are encouraged to dial 201-689-8261 a few minutes before the start time of 4:30 p.m. ET. If you miss the live session, don't worry! A replay will be made available shortly after the event concludes, and can be accessed by calling the toll-free number 877-660-6853 or 201-612-7415, using conference number 13758212.
Webcast Information
In addition to the telephonic participation, Artivion provides an opportunity to watch the proceedings via a live webcast. Investors and interested parties can tune in to the webcast through the Investors section of the Artivion website. By selecting the 'Webcasts & Presentations' link, listeners can gain access to a detailed look at the financial performance, along with projections and plans for the future. A copy of the earnings press release will also be accessible on the site, offering further details about the quarterly and annual financial metrics.
About Artivion, Inc.
Artivion, Inc. is headquartered in suburban Atlanta, Georgia, and it has distinguished itself as a medical device company dedicated to addressing significant challenges faced by cardiac and vascular surgeons. The company is focused on developing effective solutions for aortic diseases. Their impressive portfolio includes innovative products such as aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable human tissues, underscoring their commitment to advancing patient care. Artivion markets its products across more than 100 countries worldwide, making a profound impact in the medical field.
Contact Information
Artivion invites interested parties to reach out for more information. Lance A. Berry, who serves as the Executive Vice President, Chief Operating Officer & CFO, can be reached at 770-419-3355. Additionally, associates from Gilmartin Group LLC, including Brian Johnston and Laine Morgan, are available for inquiries at 332-895-3222.
Frequently Asked Questions
What is the purpose of the teleconference call?
The teleconference is designed to discuss Artivion's fourth quarter financial results and engage with investors through a question-and-answer segment.
How can I access the teleconference details?
Interested participants can access the teleconference by calling in a few minutes before the start time or by viewing the webcast on Artivion's website.
Who is leading the teleconference call?
Pat Mackin, the Chairman, President, and CEO of Artivion, will lead the teleconference call.
Where can the financial results be found?
The financial results will be released on Artivion's website, along with a detailed press release on the earnings.
What are the key products offered by Artivion?
Artivion's key products include aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues.
